scholarly journals Assessment of Molecular Markers of Anti-malarial Drug Resistance in Pfk13-propeller, Pfcrt and Pfmdr1 Genes in Plasmodium Falciparum Isolated From Patients Returning for Malaria Retreatment in Democratic Republic of Congo 

2020 ◽  
Author(s):  
Doudou Malekita Yobi ◽  
Nadine K. Kayiba ◽  
Dieudonné M. Mvumbi ◽  
Raphael Boreux ◽  
Pius Z. Kabututu ◽  
...  

Abstract BackgroundThe Democratic Republic of Congo (DRC) malaria treatment policy recommends two first-line artemisinin-based combination therapies (ACTs) for the treatment of uncomplicated malaria: Artesunate-amodiaquine (ASAQ) and Artemether-lumefantrine (AL). This study investigated resistance to the ACTs currently in use in DRC through molecular markers in pfk13, pfcrt and pfmdr1 genes in Plasmodium falciparum isolated from patients returning for malaria retreatment. MethodsFrom November 2018 to November 2019, dried blood spots were taken from patients returning to health structures for fever within 28 days after an initial malaria treatment in 6 sentinel sites of National Malaria Control Programme (NMCP) across DRC. The new episode of malaria was first detected by a rapid diagnostic test (RDT) and then confirmed by a real-time PCR assay. Fragments of interest in pfk13 and pfcrt genes were amplified by conventional PCR before sequencing and Pfmdr1 gene copy number was determined by a TaqMan real-time PCR assay. ResultsOut of 474 enrolled patients, 364 (76.8%) were confirmed positive by PCR for P. falciparum. Of the 325 P. falciparum isolates successfully sequenced in pfk13-propeller gene, 7 (2.2%) carried non-synonymous (NS) mutations among which 3 previously reported (N498I, N554K and A557S) and 4 not yet reported (F506L, E507V, D516E and G538S). Of the 335 isolates successfully sequenced in pfcrt gene, 139 (41.5%) harbored the K76T mutation known to be associated with CQ resistance. The SVMNT haplotype associated with resistance to AQ has not been found. None of the isolates carried increased copy number of pfmdr1 gene among the 322 P. falciparum isolates successfully analyzed.ConclusionNo molecular marker known to date as associated with resistance to first-line ACTs in use was detected in P. falciparum isolated in patients returning for retreatment. Regular monitoring through in vivo drug efficacy and molecular studies must continue to ensure the effectiveness of the treatment of malaria in DRC.

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Doudou M. Yobi ◽  
Nadine K. Kayiba ◽  
Dieudonné M. Mvumbi ◽  
Raphael Boreux ◽  
Pius Z. Kabututu ◽  
...  

Abstract Background The national policy for malaria treatment of the Democratic Republic of Congo recommends two first-line artemisinin-based combinations for the treatment of uncomplicated malaria: artesunate-amodiaquine and artemether-lumefantrine. This study investigated the presence of markers associated with resistance to the current first-line artemisinin-based combination therapy (ACT) in isolates of Plasmodium falciparum from treatment failure patients in the Democratic Republic of Congo. Methods From November 2018 to November 2019, dried blood spots were taken from patients returning to health centres for fever within 28 days after an initial malaria treatment in six sentinel sites of the National Malaria Control Programme across Democratic Republic of Congo. The new episode of malaria was first detected by a rapid diagnostic test and then confirmed by a real-time PCR assay to define treatment failure. Fragments of interest in pfk13 and pfcrt genes were amplified by conventional PCR before sequencing and the Pfmdr1 gene copy number was determined by a TaqMan real-time PCR assay. Results Out of 474 enrolled patients, 364 (76.8%) were confirmed positive by PCR for a new episode of P. falciparum malaria, thus considered as treatment failure. Of the 325 P. falciparum isolates obtained from 364 P. falciparum-positive patients and successfully sequenced in the pfk13-propeller gene, 7 (2.2%) isolates carried non-synonymous mutations, among which 3 have been previously reported (N498I, N554K and A557S) and 4 had not yet been reported (F506L, E507V, D516E and G538S). Of the 335 isolates successfully sequenced in the pfcrt gene, 139 (41.5%) harboured the K76T mutation known to be associated with chloroquine resistance. The SVMNT haplotype associated with resistance to amodiaquine was not found. None of the isolates carried an increased copy number of the pfmdr1 gene among the 322 P. falciparum isolates successfully analysed. Conclusion No molecular markers currently known to be associated with resistance to the first-line ACT in use were detected in isolates of P. falciparum from treatment failure patients. Regular monitoring through in vivo drug efficacy and molecular studies must continue to ensure the effectiveness of malaria treatment in Democratic Republic of Congo.


2006 ◽  
Vol 75 (1) ◽  
pp. 152-154 ◽  
Author(s):  
SANDRA COHUET ◽  
MICHEL VAN HERP ◽  
UMBERTO D’ALESSANDRO ◽  
MARYLINE BONNET ◽  
CHANTAL VAN OVERMEIR ◽  
...  

2015 ◽  
Vol 60 (4) ◽  
Author(s):  
Roger D. Wumba ◽  
Josué Zanga ◽  
Kennedy M. Mbanzulu ◽  
Madone N. Mandina ◽  
Aimé K. Kahindo ◽  
...  

AbstractCryptosporidium is an important protozoan parasite affecting HIV/AIDS patients. To determine the prevalence and the species of Cryptosporidium spp by developing a rapid and efficient real-time PCR-RFLP test. A cross-sectional study was conducted among HIV-infected adults from Kinshasa, the Democratic Republic of Congo. Stool specimens were examined by microscopic evaluation and real-time PCR-RFLP. Out of 242 HIV-infected adults, 10 (4.1%) cases of Cryptosporidium were identified by microscopic examination. Using PCR-RFLP, the prevalence of Cryptosporidium spp was 5.4% (n = 13). All the 13 cases of Cryptosporidium spp had the stage of AIDS of HIV infection. Extracted DNA was amplified by nested PCR targeting a 1030-bp fragment of the 18s RNA gene. RFLP analysis identified one C. parvum, four C. hominis and one non determined Cryptosporidium. The capacity to detect C. parvum, C. hominis and non-determined Cryptosporidium was present among our HIV-infected patients.


2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Roger Wumba ◽  
Menotti Jean ◽  
Longo-Mbenza Benjamin ◽  
Mandina Madone ◽  
Kintoki Fabien ◽  
...  

Objective. To determine the prevalence and the genotypes ofEnterocytozoon bieneusiin stool specimens from HIV patients.Methods. This cross-sectional study was carried out in Kinshasa hospitals between 2009 and 2012. Detection of microsporidia includingE. bieneusiandE. intestinaliswas performed in 242 HIV-infected patients. Typing was based on DNA polymorphism of the ribosomal DNA ITS region ofE. bieneusi. PCRRFLP generated with two restriction enzymes (Nla III and Fnu 4HI) in PCR-amplified ITS products for classifying strains into different lineages. The diagnosis performance of the indirect immune-fluorescence-monoclonal antibody (IFI-AcM) was defined in comparison with real-time PCR as the gold standard.Results. Out of 242 HIV-infected patients, using the real-time PCR, the prevalence ofE. bieneusiwas 7.9% (n=19) among the 19E. bieneusi, one was coinfected withE. intestinalis. In 19E. bieneusipersons using PCR-RFLP method, 5 type I strains ofE. bieneusi(26.3%) and 5 type IV strains ofE. bieneusi(26.3%) were identified. The sensitivity of IFI-AcM was poor as estimated 42.1%.Conclusion. Despite different PCR methods, there is possible association between HIVinfection, geographic location (France, Cameroun, Democratic Republic of Congo), and the concurrence of type I and type IV strains.


2008 ◽  
Vol 375 (1) ◽  
pp. 150-152 ◽  
Author(s):  
Cheng Xin Yi ◽  
Jun Zhang ◽  
Ka Man Chan ◽  
Xiao Kun Liu ◽  
Yan Hong

PLoS ONE ◽  
2017 ◽  
Vol 12 (6) ◽  
pp. e0179142 ◽  
Author(s):  
Dieudonné Makaba Mvumbi ◽  
Thierry Lengu Bobanga ◽  
Jean-Marie Ntumba Kayembe ◽  
Georges Lelo Mvumbi ◽  
Hippolyte Nani-Tuma Situakibanza ◽  
...  

2007 ◽  
Vol 45 (9) ◽  
pp. 2889-2893 ◽  
Author(s):  
J. Keen ◽  
G. A. Farcas ◽  
K. Zhong ◽  
S. Yohanna ◽  
M. W. Dunne ◽  
...  

2020 ◽  
Author(s):  
Doudou M. Yobi ◽  
Nadine K. Kayiba ◽  
Dieudonné M. Mvumbi ◽  
Raphael Boreux ◽  
Pius Z. Kabututu ◽  
...  

Abstract Background: The loss of chloroquine (CQ) effectiveness has led to its withdrawal from national policies as a first-line treatment for uncomplicated malaria in several endemic countries, such as the Democratic Republic of Congo (DRC). The K76T mutation on the pfcrt gene has been identified as a marker of CQ resistance and the SVMNT haplotype in codons 72–76 on the same gene has been associated with resistance to amodiaquine (AQ). In the DRC, the prevalence of K76T has decreased from 100% in 2000 to 63.9% in 2014. The purpose of this study was to determine the prevalence of K76T mutations in circulating strains of Plasmodium falciparum, sixteen years after CQ withdrawal in the DRC and to investigate the presence of the SVMNT haplotype. Methods : In 2017, ten geographical sites across the DRC were selected. Dried blood samples were collected from patients attending health centres. Malaria was first detected by a rapid diagnostic test (RDT) available on site (SD Bioline Malaria Ag Pf or CareStart Malaria Pf) or thick blood smear and then confirmed by a P. falciparum species-specific real-time PCR assay. A pfcrt gene segment containing a fragment that encodes amino acids at positions 72-76 was amplified by conventional PCR before sequencing. Results: A total of 1070 patients were enrolled. Of the 806 PCR-confirmed P. falciparum positive samples, 764 were successfully sequenced. The K76T mutation was detected in 218 samples (28.5%; 95% CI: 25.4%–31.9%), mainly (96%) with the CVIET haplotype. Prevalence of CQ resistance marker was unequally distributed across the country, ranging from 1.5% in Fungurume to 89.5% in Katana. The SVMNT haplotype, related to AQ resistance, was not detected. Conclusion: Overall, the frequency of the P. falciparum CQ resistance marker has decreased significantly and no resistance marker to AQ was detected in the DRC in 2017. However, the between regions variability of CQ resistance remains high in the country. Further studies are needed for continuous monitoring of the CQ resistance level for its prospective re-use in malaria management. The absence of the AQ resistance marker is in line with the use of this drug in the current DRC malaria treatment policy.


Sign in / Sign up

Export Citation Format

Share Document